What starts as a simple Halloween side project quickly becomes a fascinating experiment in internet art, ownership, and ...

Nature is always performing chemistry experiments, and in the dark and sticky corners of its forests and jungles, it creates compounds that have hyper-specific effects on the human mind. In China’s ...

UC Davis researchers created brand-new psychedelic-like compounds by shining UV light on amino acid-based molecules. These compounds activated key serotonin receptors tied to brain plasticity and ...

A psychedelic trip—on “magic mushrooms,” to be precise—may cause physical changes to the brain, a new imaging study finds. The results could one day help explain why people who take psilocybin—a ...

The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies to treat depression and post-traumatic stress disorder (PTSD), the latest ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

The FDA announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. It's a significant step toward supporting psychedelic-based medicines ...

The Food and Drug Administration on Friday granted a quick review of three experimental psychedelic drugs meant to treat major depression and post-traumatic stress disorder. Subscribe to read this ...

President Trump’s executive order loosening research restrictions on psychedelic medicine, which was kick-started by a text to Trump from podcaster Joe Rogan, could help legitimize an industry that’s ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Shares of biotech firms and companies providing psychedelic-assisted therapy surged on Monday, after analysts applauded an executive order from President Donald Trump that expedited research of some ...

April 20 (Reuters) - Shares of psychedelic drug developers rose on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews ‌of psychedelic ...